AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8031162 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (no chemotherapy)
Number of subjects: 200
Study 2524386 — intervention group
Group type: EXPERIMENTAL
Intervention: xipamide 20 mg once daily
Number of subjects: 12
Study 2524386 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 4574043 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniospinal irradiation
Number of subjects: 0
Study 4574043 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 30295116 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 49
Study 30295116 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phenylalanine tyrosine depletion (APTD)
Number of subjects: 49
Study 30295116 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid mixture (BAL)
Number of subjects: 49
Study 31236943 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed modeling workflow for DVH prediction
Number of subjects: 268
Study 31236943 — intervention group
Group type: EXPERIMENTAL
Intervention: Replanned cases guided by the proposed model
Number of subjects: 268
Study 31236943 — intervention group
Group type: COMPARATOR
Intervention: Conventional knowledge-based model
Number of subjects: 268
Study 28682918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure as an adjunctive therapy to sodium valproate (ASV)
Number of subjects: 98
Study 28682918 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate alone (SV)
Number of subjects: 98
Study 25970485 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hyperbaric (4 mg) and hypobaric (6 mg) ropivacaine (Group A)
Number of subjects: 136
Study 25970485 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric ropivacaine (Group B)
Number of subjects: 136
Study 23108937 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg, then 150 mg)
Number of subjects: 369
Study 23108937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 21736751 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg SC every 4 weeks
Number of subjects: 274
Study 21736751 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg SC every 2 weeks
Number of subjects: 274
Study 21736751 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 600 mg IV loading dose followed by 300 mg SC every 2 weeks
Number of subjects: 274
Study 21736751 — intervention group
Group type: COMPARATOR
Intervention: Placebo SC every 2 weeks
Number of subjects: 274
Study 19564303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing (SDB)
Number of subjects: 194
Study 16401655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (Eth; mean blood alcohol concentration at 60 min: 87.3, SD: 18.4)
Number of subjects: 11
Study 16401655 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 30 mg (P30)
Number of subjects: 11
Study 16401655 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 11
Study 16401655 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 20 mg (P20)
Number of subjects: 11
Study 15501626 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.25 microg/kg/minute) with target controlled infusion of propofol (target blood concentration: 1.5 to 2 microg/ml)
Number of subjects: 338
Study 15501626 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil (1 microg/kg/minute) with manually controlled infusion of propofol
Number of subjects: 338
Study 11519700 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 15
Study 11519700 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMD)
Number of subjects: 15
Study 11519700 — intervention group
Group type: COMPARATOR
Intervention: Coronally repositioned flap surgery (control)
Number of subjects: 15
Study 9283858 — intervention group
Group type: EXPERIMENTAL
Intervention: Heater probe
Number of subjects: 31
Study 9283858 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection sclerosis
Number of subjects: 31
Study 9283858 — intervention group
Group type: COMPARATOR
Intervention: Medical-surgical treatment
Number of subjects: 31
Study 8518898 — intervention group
Group type: EXPERIMENTAL
Intervention: Angelchik prosthesis
Number of subjects: 119
Study 8518898 — intervention group
Group type: COMPARATOR
Intervention: Floppy Nissen fundoplication
Number of subjects: 119
Study 8518898 — intervention group
Group type: EXPERIMENTAL
Intervention: Angelchik prosthesis (consecutive series)
Number of subjects: 119
Study 8518898 — intervention group
Group type: EXPERIMENTAL
Intervention: Angelchik prosthesis and floppy Nissen fundoplication
Number of subjects: 119
Study 3552838 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 11806
Study 3552838 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 11806
Study 29540866 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented pancreatico‐jejunostomy
Number of subjects: 102
Study 29540866 — intervention group
Group type: COMPARATOR
Intervention: Non-stented pancreatico‐jejunostomy
Number of subjects: 102
Study 29540866 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft pancreatic texture
Number of subjects: 102
Study 29540866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct <3mm
Number of subjects: 102
Study 27484507 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training loaded with 40% of maximum inspiratory pressure, readjusted weekly
Number of subjects: 0
Study 27484507 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention consisting of unloaded exercises
Number of subjects: 0
Study 27484507 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 0
Study 24626738 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group (indicated sample)
Number of subjects: 229
Study 24626738 — intervention group
Group type: COMPARATOR
Intervention: Control group (indicated sample)
Number of subjects: 229
Study 24626738 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group (selective high-risk sample)
Number of subjects: 229
Study 22568863 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1482160 (up to 1 g, single doses)
Number of subjects: 29
Study 20022990 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) 4 mg iv every 3 months for 12 months
Number of subjects: 101
Study 20022990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 19246793 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU twice daily)
Number of subjects: 24
Study 19246793 — intervention group
Group type: COMPARATOR
Intervention: Placebo (standard therapy only)
Number of subjects: 24
Study 15719740 — intervention group
Group type: EXPERIMENTAL
Intervention: Shentao Ruangan pill (SRP) combined with local perfusion of hydroxycamptothecine (HCPT)
Number of subjects: 85
Study 15719740 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 85
Study 12949315 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.5 mg (total daily dose) once or twice daily
Number of subjects: 335
Study 12949315 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn sodium nebulizer solution 20 mg 4 times daily
Number of subjects: 335
Study 12949315 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension
Number of subjects: 335
Study 12949315 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension and cromolyn sodium
Number of subjects: 335
Study 12949315 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn sodium
Number of subjects: 335
Study 10715305 — intervention group
Group type: EXPERIMENTAL
Intervention: (111)In-DTPA-D-Phe(1)-OCT
Number of subjects: 194
Study 8941260 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 0
Study 8941260 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based, planned care; reorganization of practice systems; improved patient self-management support; increased access to expertise; greater availability of clinical information
Number of subjects: 0
Study 8941260 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated system of chronic illness care
Number of subjects: 0
Study 1634632 — intervention group
Group type: EXPERIMENTAL
Intervention: Light energy conversion toothbrush with semiconductor of TiO2 (test)
Number of subjects: 73
Study 1634632 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush without semiconductor (control)
Number of subjects: 73
Study 6365017 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadyl acetate three times a week (tiw) with placebos on alternate days
Number of subjects: 255
Study 6365017 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadyl acetate tiw supplemented with decreasing doses of methadone on alternate days
Number of subjects: 255
Study 6365017 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadyl acetate six days a week with diminishing doses on three days
Number of subjects: 255
Study 6365017 — intervention group
Group type: COMPARATOR
Intervention: Supplementary methadyl acetate along with the regular dose
Number of subjects: 255
Study 6365017 — intervention group
Group type: COMPARATOR
Intervention: Supplementing with methadone
Number of subjects: 255
Study 30497530 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy with bevacizumab
Number of subjects: 123
Study 30497530 — intervention group
Group type: COMPARATOR
Intervention: neoadjuvant chemotherapy without bevacizumab
Number of subjects: 123
Study 26724840 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA ≥ 3.0 + MRI + TB
Number of subjects: 124
Study 26724840 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA ≥ 1.8 + MRI + TB
Number of subjects: 124
Study 26724840 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA ≥ 3.0 + MRI
Number of subjects: 124
Study 26724840 — intervention group
Group type: COMPARATOR
Intervention: PSA ≥ 3.0 + SB
Number of subjects: 124
Study 23632404 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical brimonidine tartrate (BT)
Number of subjects: 56
Study 23632404 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide (ACZ)
Number of subjects: 56
Study 23632404 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior chamber paracentesis (ACP)
Number of subjects: 56
Study 23632404 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 56
Study 22633593 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia (Lava) 3-unit posterior fixed dental prostheses
Number of subjects: 17
Study 20339912 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of children with ADHD
Number of subjects: 124
Study 20339912 — intervention group
Group type: COMPARATOR
Intervention: Parents of comparison youth
Number of subjects: 124
Study 20339912 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental behaviors (socialization with other parents, facilitation of child's peer interactions)
Number of subjects: 124
Study 20339912 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental corrective feedback and praise
Number of subjects: 124
Study 20339912 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' ratings of child's social skills
Number of subjects: 124
Study 20339912 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental behaviors and peer relationships
Number of subjects: 124
Study 18587144 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshops on urine submission
Number of subjects: 82
Study 18587144 — intervention group
Group type: COMPARATOR
Intervention: Modified laboratory forms
Number of subjects: 82
Study 18587144 — intervention group
Group type: COMPARATOR
Intervention: Control workshop
Number of subjects: 82
Study 16113791 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (0.8 mg/day) for 1 year
Number of subjects: 276
Study 16113791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 12855344 — intervention group
Group type: EXPERIMENTAL
Intervention: Momentary monitoring of pain with an electronic diary
Number of subjects: 91
Study 10673886 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microgram kg‐1
Number of subjects: 40
Study 10673886 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study 10673886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 8607397 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (median dose, 200 mg/day)
Number of subjects: 121
Study 8607397 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (median dose, 240 mg/day)
Number of subjects: 121
Study 8607397 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 121
Study 8607397 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 121
Study 8607397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 121
Study 1850344 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.6 mg/kg/day)
Number of subjects: 16
Study 1850344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6171491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran‐40
Number of subjects: 57
Study 6171491 — intervention group
Group type: COMPARATOR
Intervention: Hartman's solution
Number of subjects: 57
Study 31797446 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program (12-week program including intensive counseling, education, and telephone calls)
Number of subjects: 115
Study 31008987 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel circumcision method (subcutaneous tissue-sparing dorsal slit with new marking)
Number of subjects: 93
Study 31008987 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection
Number of subjects: 93
Study 28275838 — intervention group
Group type: EXPERIMENTAL
Intervention: Catch a Break (CaB) FLS
Number of subjects: 7323
Study 26116491 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Toothbrushing (STB)
Number of subjects: 242
Study 26116491 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Resin (CR)
Number of subjects: 242
Study 26116491 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment - High-Viscosity Glass-Ionomer Cement (ART-GIC)
Number of subjects: 242
Study 26116491 — intervention group
Group type: COMPARATOR
Intervention: No Intervention
Number of subjects: 242
Study 23363655 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention program
Number of subjects: 0
Study 23363655 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 0
Study 21052775 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with ACNU (40 mg/m(2)/day) and CDDP (40 mg/m(2)/day) infused continuously for 72 h followed by radiotherapy and adjuvant temozolomide (150‐200 mg/m(2) for 5 days every 28 days)
Number of subjects: 82
Study 21052775 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy followed by adjuvant temozolomide (150‐200 mg/m(2) for 5 days every 28 days)
Number of subjects: 82
Study 19671350 — intervention group
Group type: EXPERIMENTAL
Intervention: upstream tirofiban (4-6 hours prior to PCI)
Number of subjects: 160
Study 19671350 — intervention group
Group type: COMPARATOR
Intervention: downstream tirofiban (immediately prior to PCI)
Number of subjects: 160
Study 19671350 — intervention group
Group type: EXPERIMENTAL
Intervention: upstream tirofiban
Number of subjects: 160
Study 19671350 — intervention group
Group type: COMPARATOR
Intervention: downstream tirofiban
Number of subjects: 160
Study 17237646 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal extracorporeal circuit (MECC)
Number of subjects: 60
Study 17237646 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiopulmonary bypass (CPB)
Number of subjects: 60
Study 15093577 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and paclitaxel
Number of subjects: 275
Study 15093577 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin and cyclophosphamide
Number of subjects: 275
Study 14556826 — intervention group
Group type: EXPERIMENTAL
Intervention: Short coincubation of gametes for 2 hours (group 1)
Number of subjects: 259
Study 14556826 — intervention group
Group type: COMPARATOR
Intervention: Prolonged incubation of gametes for 20 hours (group 2)
Number of subjects: 259
Study 10446118 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion containing long chain triglycerides
Number of subjects: 30
Study 10446118 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion containing a mixture of long and medium chain triglycerides
Number of subjects: 30
Study 8848889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (5 mg intravenous bolus injections)
Number of subjects: 40
Study 8848889 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (40 micrograms intravenous bolus injections)
Number of subjects: 40
Study 2081789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (500 mg/kg)
Number of subjects: 577
Study 2081789 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% albumin-normal saline, 10 ml/kg)
Number of subjects: 577
Study 6986007 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg oxatomide b.i.d.
Number of subjects: 91
Study 6986007 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg/kg diphenhydramine b.i.d.
Number of subjects: 91
Study 31752042 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine GPI administration before primary PCI
Number of subjects: 1630
Study 31752042 — intervention group
Group type: EXPERIMENTAL
Intervention: Bailout GPI administration
Number of subjects: 1630
Study 31752042 — intervention group
Group type: COMPARATOR
Intervention: No GPI
Number of subjects: 1630
Study 31752042 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine GPI administration
Number of subjects: 1630
Study 30730541 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV2/2-ND4 (9×109, 3×1010, 9×1010, and 1.8×1011 viral genomes per eye) as a single unilateral intravitreal injection
Number of subjects: 15
Study 30730541 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV2/2-ND4
Number of subjects: 15
Study 28760390 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Heating System (THS) 2.2
Number of subjects: 62
Study 28760390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes (CC)
Number of subjects: 62
Study 28760390 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Gum (Gum)
Number of subjects: 62
Study 25047652 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodiagnostic testing with physical therapy (specific interventions not detailed)
Number of subjects: 38
Study 24043742 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple intensity-modulated radiotherapy (IMRT)
Number of subjects: 1145
Study 24043742 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (RT)
Number of subjects: 1145
Study 21544070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (DA agonist)
Number of subjects: 8
Study 21544070 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (indirect NE agonist)
Number of subjects: 8
Study 21544070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (ACh agonist)
Number of subjects: 8
Study 21544070 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (DA antagonist)
Number of subjects: 8
Study 21544070 — intervention group
Group type: COMPARATOR
Intervention: Prazosine (NE antagonist)
Number of subjects: 8
Study 21544070 — intervention group
Group type: COMPARATOR
Intervention: Biperiden (ACh antagonist)
Number of subjects: 8
Study 19039224 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/DDCI and entacapone
Number of subjects: 0
Study 19039224 — intervention group
Group type: COMPARATOR
Intervention: dose fractionation
Number of subjects: 0
Study 17726362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endurance and resistance training (3 hours a week for one year)
Number of subjects: 40
Study 17726362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in everyday activities)
Number of subjects: 40
Study 15205602 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy with cisplatin
Number of subjects: 6
Study 15205602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral (i.t.) administration of cisplatin
Number of subjects: 6
Study 15205602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 6
Study 11349741 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fludarabine 30 mg/m2/day
Number of subjects: 5
Study 11349741 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fludarabine 30 mg/m2/day
Number of subjects: 5
Study 11349741 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fludarabine
Number of subjects: 5
Study 11349741 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fludarabine
Number of subjects: 5
Study 9847430 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 16
Study 9847430 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 16
Study 30793735 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring-only (HMo) based on remote monitoring (RM) + remote interrogations (RIs) every 6 months
Number of subjects: 445
Study 30793735 — intervention group
Group type: COMPARATOR
Intervention: HM + IO (Home Monitoring + In-Office evaluations) every 6 months
Number of subjects: 445
Study 30793735 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring-only (HMo)
Number of subjects: 445
Study 30793735 — intervention group
Group type: COMPARATOR
Intervention: HM + IO
Number of subjects: 445
Study 28831241 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone 50 mg
Number of subjects: 158
Study 28831241 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone 100 mg
Number of subjects: 158
Study 28831241 — intervention group
Group type: COMPARATOR
Intervention: Control (ACE inhibitors or AT1R antagonists plus HCT without canrenone)
Number of subjects: 158
Study 25367200 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive mesh (Parietene Progrip®)
Number of subjects: 89
Study 25367200 — intervention group
Group type: COMPARATOR
Intervention: Conventional Lichtenstein hernioplasty (polypropylene mesh)
Number of subjects: 89